![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc in Treatment-Naive Patients
|
|
|
Reported by Jules Levin
Glasgow 2010 Nov 7-11
D Chapman1, P Biswas2, M Lewis3, C Craig3, J Heera4, S Ellery4, L Swenson5, PR Harrigan5, H Valdez1
Pfizer Inc, New York, NY, USA; 2Pfizer Inc, Collegeville, PA, USA; 3Pfizer Global Research and Development, Sandwich, UK; 4Pfizer PGRD New London, CT, USA; 5BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
![](../images/111710/111710-2/cons-1.gif)
![](../images/111710/111710-2/object-2.gif)
![](../images/111710/111710-2/results-3.gif)
![](../images/111710/111710-2/charca-4.gif)
![](../images/111710/111710-2/merit-5.gif)
![](../images/111710/111710-2/RNA-6.gif)
![](../images/111710/111710-2/ana-7.gif)
![](../images/111710/111710-2/pred-8.gif)
![](../images/111710/111710-2/ref-9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|